Cem Mirili

7PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersNutrigenomics and personalised nutrition
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 27, 2026
First-Line Palbociclib/Letrozole Versus Ribociclib/Letrozole in Postmenopausal HR-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Real-World Study and an Exploratory Composite Clinical-Inflammatory Risk Score.

|Aug 13, 2026
First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.

|Jun 26, 2026
Enzalutamide Versus Abiraterone After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Real-World Outcomes and Exploratory Prognostic Stratification.

|Oct 16, 2020
Inflammatory Markers Predicting Pathological Complete Response in Cases with Breast Cancer Treated by Neoadjuvant Chemotherapy.

Mahmut Büyükşimşek, Ali Oğul, Cem Mirili

|Mar 19, 2020
The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen.

Mahmut Buyuksimsek, Mehmet Mutlu Kidi, Ali Ogul

|May 11, 2019
Clinical significance of prognostic nutritional index (PNI) in malignant melanoma.

Cem Mirili, Ali Yılmaz, Serkan Demirkan

Pageof 2

Frequent Collaborators

4 joint publications

Mahmut Buyuksimsek

3 joint publications

Ali Ogul

2 joint publications

Semra Paydas

2 joint publications

Mert Tohumcuoğlu